Sanjeev Luther
President & Chief Executive Officer Ernexa Therapeutics
Seminars
Monday 7th December 2026
Panel Discussion: Strengthening Vendor Partnerships to Secure Reliable Material Supply & Quality Standards
1:30 pm
- Building strategic relationships with blood banks, apheresis centers and cord blood banks to ensure consistent material availability and quality alignment
- Establishing clear communication of donor requirements, testing specifications and delivery expectations with external partners to prevent misalignment
- Auditing supplier capabilities, quality systems and regulatory compliance to qualify vendors that can support long-term commercial needs
Tuesday 8th December 2026
Chair’s Opening Remarks
8:55 am
Tuesday 8th December 2026
Roundtable Discussion: Improving Donor Recruitment & Retention to Ensure Reliable Access to High- Performing Donors
11:30 am
- Sharing successful donor engagement strategies to improve retention rates and facilitate efficient re-collection when additional manufacturing is required
- Identifying key drivers of donor attrition to develop practical retention programs that increase long-term donor commitment
- Collaborating with apheresis centres, blood banks and donor registries to strengthen recruitment pipelines and expand access to diverse donor populations
Tuesday 8th December 2026
Optimizing Donor Consent Frameworks to Enable Compliant & Scalable Microbiome Research Session Highlights
12:15 pm
- Implementing dynamic consent models to strengthen donor engagement while supporting long-term microbiome sample utilization
- Harmonizing consent language across collection sites to reduce regulatory risk and improve global study scalability
- Establishing governance processes for secondary sample use to maximize research value while maintaining donor trust
Tuesday 8th December 2026
Roundtable Discussion: Preparing for In Vivo Therapies to Protect Market Position & Adapt Sourcing Strategies for Long-Term Competitiveness
3:15 pm
- Examining whether in vivo CAR-T and gene therapy approaches could reduce demand for ex vivo cell manufacturing and donor sourcing infrastructure
- Discussing how the allogeneic cell therapy field should respond to competitive pressure from in vivo modalities to maintain relevance and investment
- Evaluating whether suppliers, CDMOs and technology providers will sustain business models if market demand shifts toward in vivo approaches
Tuesday 8th December 2026
Chairs’ Closing Remarks
5:15 pm
